Using the TIMER database, we found that the expression of TACR2 was significantly downregulated in a variety of cancer tissues, including prostate cancer, clear cell renal cell carcinoma, chromophobe tumor, and papillary renal cell carcinoma. Here, TACR2 is linked to prostate carcinoma.